Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Inclusion Criteria: * Before any research-related operations, they should sign the informed consent Consent Form (ICF) (Genotype and Tumor Antigen Screening and Primary Screening); * Age ≥18 years, and ≤70 years; * His/cytology confirmed, unresectable or metastatic soft tissue sarcoma; * The current stage is the failure of standard treatment (disease progression or recurrence or intolerance, such as chemotherapy, radiotherapy, targeted therapy, etc.) or lack of effective treatment methods, specifically: In addition to acinar soft tissue sarcoma and for pathological subtypes other than epithelioid sarcoma, at least adriamycin or doxorubicin combined with ifosfamide standard chemotherapy regimen should fail or not tolerate chemotherapy; For acinar soft tissue sarcoma and epithelioid sarcoma, need failure or intolerance of previous targeted drugs \[anti-angiogenesis such as Anlotinib, pazopanib, etc.\]; Note: Treatment failure refers to disease progression or inability during treatment or within 3 months of the last treatment Tolerable; disease progression in patients with neoadjuvant or adjuvant therapy \> 6 months after the end of treatment can be considered first-line therapy; * At least 1 measurable lesion (according to RECIST1.1 criteria \[see Appendix 4 for details\]); * Genotype and tumor antigen screening must meet the following 2 criteria: HLA-A\*02:01 positive; NY-ESO-1\* positive: immunohistochemical staining positive cells are ≥20%; * ECOG score of 0-1 and expected …